RNA测序识别人类胶质母细胞瘤中可治疗靶向的免疫激活决定因素
研究利用TCGA的RNA-seq数据,对109例初治原发性胶质母细胞瘤(GBM)分析28种可治疗靶向的肿瘤微环境(TME)因子mRNA表达与免疫细胞溶解活性(CYT)的独立关联,并在中国胶质瘤协作组(CGCG)52例新诊断GBM中验证。多因素线性回归显示CSF-1、CD137、VEGF-A(负相关)、CTLA4、CD40、GITR、IL6、OX40与CYT独立相关;CGCG队列中仅CTLA4和CD40在多因素分析中保持统计学显著。作者认为结果可为GBM的合理免疫联合方案提供依据。
要点
- 在TCGA的109例初治原发性GBM中,CSF-1、CD137、CTLA4、CD40、GITR、IL6、OX40与CYT正相关,VEGF-A与CYT负相关。
- 在CGCG的52例新诊断GBM中,上述关联除VEGF-A外单因素分析均保持显著,多因素分析仅CTLA4和CD40达统计学显著。
- 作者认为这些可治疗靶向的TME因子可为GBM的合理免疫联合方案提供依据。
核心结论
- 利用RNA-seq基因表达数据的多因素建模,识别了与人类GBM瘤内细胞溶解性T细胞活性独立相关的可治疗靶向TME因子。
- 鉴于目前已有众多系统性免疫治疗可供研究,作者认为结果可为GBM的合理联合方案评估提供依据。
研究设计与样本
- 研究访问GlioVis获取癌症基因组图谱(TCGA)的RNA-seq数据,纳入初治原发性GBM受试者。
- 对每例肿瘤量化28种可治疗靶向TME因子的mRNA表达,并计算CYT(GZMA与PRF1表达的几何均值)。
- 采用多元线性回归分析因变量CYT与28种因子mRNA表达的关系,并在中国胶质瘤协作组(CGCG)新诊断GBM独立队列中评估多因素分析中与CYT相关的变量。
- TCGA队列分析109例肿瘤,CGCG验证队列样本量为52例。
主要发现
- 最终多元线性回归模型纳入的变量除VEGF-A(负相关)外均与CYT正相关:CSF-1(p=0.003)、CD137(p=0.042)、VEGF-A(p<0.001)、CTLA4(p=0.028)、CD40(p=0.023)、GITR(p=0.020)、IL6(p=0.02)、OX40(p<0.001)。
- 在CGCG队列(n=52)中,上述变量除VEGF-A外单因素分析均与CYT保持显著关联。
- 在CGCG队列的多因素分析中,仅CTLA4和CD40保持统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We sought to determine which therapeutically targetable immune checkpoints, costimulatory signals, and other tumor microenvironment (TME) factors are independently associated with immune cytolytic activity (CYT), a gene expression signature of activated effector T cells, in human glioblastoma (GBM). METHODS: GlioVis was accessed for RNA-seq data from The Cancer Genome Atlas (TCGA). For subjects with treatment-naïve, primary GBM, we quantified mRNA expression of 28 therapeutically targetable TME factors. CYT (geometric mean of GZMA and PRF1 expression) was calculated for each tumor. Multiple linear regression was performed to determine the relationship between the dependent variable (CYT) and mRNA expression of each of the 28 factors. Variables associated with CYT in multivariate analysis were subsequently evaluated for this association in an independent cohort of newly diagnosed GBMs from the Chinese Glioma Cooperative Group (CGCG). RESULTS: 109 TCGA tumors were analyzed. The final multiple linear regression model included the following variables, each positively associated with CYT except VEGF-A (negative association): CSF-1 (p = 0.003), CD137 (p = 0.042), VEGF-A (p < 0.001), CTLA4 (p = 0.028), CD40 (p = 0.023), GITR (p = 0.020), IL6 (p = 0.02), and OX40 (p < 0.001). In CGCG (n = 52), each of these variables remained significantly associated with CYT in univariate analysis except for VEGF-A. In multivariate analysis, only CTLA4 and CD40 remained statistically significant. CONCLUSIONS: Using multivariate modeling of RNA-seq gene expression data, we identified therapeutically targetable TME factors that are independently associated with intratumoral cytolytic T-cell activity in human GBM. As a myriad of systemic immunotherapies are now available for investigation, our results could inform rational combinations for evaluation in GBM.
引用
- Bagley SJ, Hwang WT, Brem S, et al. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. J Neurooncol. 2018. PMID: 30353265. doi:10.1007/s11060-018-03010-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。